Company intelligence / Profile preview

MicroGenDX

Ownership: Private
Employees: ~51
Development stage: Other

Overview

MicroGenDX has processed over 700,000–750,000 qPCR+NGS samples in its CAP-accredited, CLIA-certified lab. Its technology demonstrates higher sensitivity and accuracy than traditional culture methods for diagnosing infectious diseases. Clinical studies have shown improved detection rates in urinary tract and orthopedic/prosthetic joint infection settings.

Therapeutic areas: Infectious Diseases
Modalities: Diagnostic deviceNext-generation sequencing-based diagnostic testqPCR-based diagnostic test
Industry: Molecular Diagnostics

Partnerships

Collaborated with FDA on endoscope safety study; multicenter orthopedic PJI study partners.No major pharma/biotech partnerships disclosed publicly as of June 2025.

Beyond the preview

Go deeper on MicroGenDX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroGenDX.

Explore the full profile